Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.78% $3.50
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 63.76 mill |
EPS: | -0.780 |
P/E: | -4.49 |
Earnings Date: | Aug 28, 2024 |
SharesOutstanding: | 18.22 mill |
Avg Daily Volume: | 0.0042 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | n/a | ||
Asset | n/a | n/a | ||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.49 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.76x |
Company: PE -4.49 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.763 (-49.63%) $-1.737 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 3.20 - 3.80 ( +/- 8.57%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2008-10-06 | Driscoll Martin J | Buy | 4 999 | Options to acquire Common Stock |
2008-04-11 | Sanders Walter Lloyd | Buy | 65 000 | Restricted Stock Unit |
2007-01-03 | Sanders Walter Lloyd | Sell | 53 | Common Stock, par value $.001 |
2007-01-03 | Sanders Walter Lloyd | Sell | 51 | Common stock, par value $.001 |
2007-07-11 | Driscoll Martin J | Buy | 30 000 | Options to acquire Common Stock |
INSIDER POWER |
---|
0.00 |
Last 60 transactions |
Buy: 9 070 639 | Sell: 19 095 969 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $3.50 (-2.78% ) |
Volume | 0.0074 mill |
Avg. Vol. | 0.0042 mill |
% of Avg. Vol | 176.45 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.